NCT04311671

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

A Randomized, Double Blind, Parallel Group Clinical Trial to Evaluate the Safety of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Treatment With Albendazole

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 12,979 (actual)
• Sponsor: Medicines Development for Global Health · Academic / Other
• Sex: All
• Age: 4 Years
• Healthy volunteers: Accepted

Summary

The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.

Conditions

• Onchocerciasis

Interventions

Type	Name	Description
DRUG	Moxidectin	2 mg tablets, encapsulated for blinding
DRUG	Ivermectin	3 mg tablets, encapsulated for blinding
DRUG	Albendazole	400 mg tablets

Timeline

• Start date: 2021-05-03
• Primary completion: 2024-09-27
• Completion: 2024-09-27
• First posted: 2020-03-17
• Last updated: 2026-03-03
• Results posted: 2026-02-05

Locations

2 sites across 2 countries: Côte d’Ivoire, Democratic Republic of the Congo

Regulatory

• FDA-regulated drug study